LP
BCAB icon

LMR Partners’s BioAtla BCAB Stock Holding History

LMR Partners’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-295
Closed -$122K – 1031
2022
Q4 		$122K Buy
+295
New +$122K ﹤0.01% 1030

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LMR Partners's BCAB Position: Q1 2023 in Review

LMR Partners sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 295 shares — an estimated $122K sold.

LMR Partners first reported a position in BCAB in Q4 2022 and held it in 1 quarter. The position peaked at $122K in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • LMR Partners reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
  • LMR Partners sold 295 BioAtla shares in Q1 2023, an estimated $122K.
  • LMR Partners first reported a position in BioAtla in Q4 2022 and held it in 1 quarter.
  • LMR Partners's BioAtla position peaked at $122K in Q4 2022.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.